Top Authors

• Most frequent coverage on RPRX

• 
  Mike Havrilla (1964 followers)

  • FDA Calendar Updates: Transcept Pharma Surges on Deal (Mon, Aug 3)
  • FDA Calendar Updates: Repros, Discovery, Acorda, Human Genome Sciences (Thu, Jul 2)
  • Five Extreme Biotech Trades (Wed, Jun 10)

  More by Mike Havrilla on RPRX »
• 
  Elliot Eisenberg (3 followers)

  • Why Michelle Obama Is Likely to Support Repros Therapeutics (Mon, Jul 13)
  • Five Reason Repros Therapeutics Is Hitting 52-Week Highs (Fri, Jan 9)
  • What's With Efficacy Capital/Repros Therapeutics' Standstill Agreement? (Tue, Jan 22)

  More by Elliot Eisenberg on RPRX »
• 
  Centient Biotech Investor (10 followers)

  • Biotech Day In Review: Cell Genesys Climbs On GVAX Results (Wed, Apr 4)
  • Biotech Stocks Day-in-Review: Genentech Buys Altus' Pipeline (Thu, Dec 21)

  More by Centient Biotech Investor on RPRX »

• Most followed authors on RPRX

• 
  Mike Havrilla (1964 followers)

  • FDA Calendar Updates: Transcept Pharma Surges on Deal (Mon, Aug 3)
  • FDA Calendar Updates: Repros, Discovery, Acorda, Human Genome Sciences (Thu, Jul 2)
  • Five Extreme Biotech Trades (Wed, Jun 10)

  More by Mike Havrilla on RPRX »
• 
  optionMONSTER (1283 followers)

  • A Three-Way Strategy on Repros Therapeutics (Mon, Oct 26)

  More by optionMONSTER on RPRX »
• 
  Frederic Ruffy (643 followers)

  • Friday's Options Recap (Fri, Aug 21)
  • Wednesday's Options Recap (Wed, Jul 1)

  More by Frederic Ruffy on RPRX »

• Newest authors on RPRX

• 
  Biomaven (1 follower)

  • Repros Therapeutics: Circling the Drain to Zero (Wed, Sep 2)

  More by Biomaven on RPRX »
• 
  M. E. Garza (564 followers)

  • Big Lineup of Healthcare Stocks Crack the Russell 3000 Index (Wed, Jul 1)

  More by M. E. Garza on RPRX »
• 
  optionMONSTER (1283 followers)

  • A Three-Way Strategy on Repros Therapeutics (Mon, Oct 26)

  More by optionMONSTER on RPRX »

• Most commented on RPRX

• 
  Elliot Eisenberg (3 followers)

  • Why Michelle Obama Is Likely to Support Repros Therapeutics (Mon, Jul 13)
  • Five Reason Repros Therapeutics Is Hitting 52-Week Highs (Fri, Jan 9)
  • What's With Efficacy Capital/Repros Therapeutics' Standstill Agreement? (Tue, Jan 22)

  More by Elliot Eisenberg on RPRX »
• 
  Biomaven (1 follower)

  • Repros Therapeutics: Circling the Drain to Zero (Wed, Sep 2)

  More by Biomaven on RPRX »
• 
  Ian Bezek (9 followers)

  • Red Flags at Repros Therapeutics (Sun, Jan 25)

  More by Ian Bezek on RPRX »